Postdoctoral position available to to come and work with us on furthering our understanding of infections and immunity across generation (oldest old and children) https://t.co/9oPEPGH6Xh
1) I feel this paper by Mattias Forsell's group is often overlooked but shows something very important: Binding antibody to SARS-CoV-2 spike - in the absence of strong neutralizing antibodies to a new variant - predict protection from mortality. https://t.co/zF4zXYeEvL.
Vaccine-induced antibodies coupled to infection- and mortality data from 3012 older individuals (median age 86) at Swedish nursing homes. https://t.co/T84irGECRD
From our collaboration with the Johansson lab, and others. @umeauniversity@KlingstromLab@BenjMurrell
The lab is recruiting! We're at Karolinska, in Stockholm. We're looking for:
- a postdoc with a computational/statistical background, with an interest in evolution and/or deep learning
- a few `wetlab' roles, including a postdoc ("antibody stuff"), and lab tech/admin folks. 1/n
Our new paper demonstrating the feasibility of at-home sampling to provide equal opportunities for serological testing in rural areas.
https://t.co/bQ2bEkXaUF
Come join our work on studies of vaccination and infections in elderly. Collaborative postdoc project with Anders Johansson (umu) and Jochen Schwenk (SciLife, KTH)
Project 16 in the ad:
https://t.co/glZi579pEx
On the 7th of October, our first grad student Andy Dernstedt defended their thesis “Life and death of human B cells in health and disease”. Here, Andy described multiple aspects of the B cell life cycle during infection and vaccination. Congratulations on your degree! 🎓🥳
Having a PhD? Interested in epidemiological research on long-term consequences of infectious diseases?
Then we have the position for you. Please share! @medfak_LU
https://t.co/WlTTGKQ9Me
Happy to share our latest publication: Anti-spike mucosal IgA protection against SARS-Cov-2 omicron infection.
Fantastic collaboration with Charlotte Thålin @SmedSorensenLab@KimBlom10 and many more!
https://t.co/QnQgUj5Spp
86% efficacy for the @pfizer RSV prefusion F vaccine in the elderly is extremely good news! Looks like there will be multiple RSV vaccines available soon for this target population. Still looking forward to seeing the data later this year from their maternal vaccine trial.
Received an email from Rino Rappuoli this morning informing me, @BarneyGrahamMD and Peter Kwong of the positive phase III data for the RSV prefusion F vaccine results in older adults. It's been almost 10 years since we designed the first prefusion RSV F antigen, DS-Cav1. Amazing!
Great work by @chengzi_kaku and @LauraMWalker2 on B cell recall after omicron/BA.1 breakthrough infection in mRNA vaccinated donors. Happy we could help out @UmeaUniversity. https://t.co/b6nEhfSIYQ
Happy to share latest paper at @scienceTM from our Prometheus consortium on broadly neutralizing antibodies against emerging hantaviruses from human convalescent donors. We're especially excited about one particular antibody we've identified. https://t.co/aqCjEcgPCZ 1/10
Come join us! We're currently recruiting 1 to 2 PhD students to work with us on human immune responses to vaccination. Apply via the Umeå University website.
https://t.co/B6QVSlaNr6